Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

NCT05680922 is registered in ClinicalTrials.gov with Legend Biotech USA Inc as lead sponsor.

NCT NCT05680922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05680922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
Lead sponsor
Legend Biotech USA Inc
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 26, 2023
Completion date
December 31, 2027
Enrollment
41 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

large cell neuroendocrine carcinoma of the lung, small cell lung cancer extensive stage